No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 40.5x · 10Y median 16.6x · 82nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 25
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:14.831Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Korro Bio, Inc. (KRRO) stock was $9.70 as of Oct 6, 2026, 10:00 AM EDT, down 2.71% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -78.3% · 3-year avg -9.6%/yr · 5-year avg -50.7%/yr
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Biotechnology · Cambridge, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-1.25
Revenue Est.
$187500.00
Last Quarter Results
EPS
$-1.07
vs Estimate
$-1.28
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KRRO | $96.55M | $9.70 | -2.71% | -78.27% | -50.72% | N/A | N/A |
| 2MIST | $96.11M | $0.77 | -0.95% | -62.89% | -33.18% | N/A | vs KRRO |
| 3ANIX | $99.18M | $2.92 | -1.19% | -9.74% | -8.26% | -4.65% | vs KRRO |
| 4BMEA | $91.82M | $1.27 | -2.31% | -39.39% | -36.56% | N/A | vs KRRO |
| 5ECOR | $91.15M | $10.11 | -0.20% | +101.52% | -8.10% | N/A | vs KRRO |
| 6JYNT | $102.92M | $7.22 | +0.49% | -20.73% | -40.34% | +11.23% | vs KRRO |
forward FY estimate
N/A
$1.50M
vs Estimate
$214286.00
Consensus Rating
Based on 10 analysts
Average Price Target
$20.20
+108.2% upside
Low
$10.00
Current
$9.70
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.56 | $-1.26 | $-1.03 | 7 |
| Quarter ending Dec 2026 | $-2.39 | $-1.29 | $-0.73 | 7 |
| Quarter ending Mar 2027 | $-1.04 | $-1.04 | $-1.04 | 2 |
| Quarter ending Jun 2027 | $-1.08 | $-1.08 | $-1.08 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-7.02 | $-5.31 | $-4.53 | 9 |
| FY 2027 | $-5.74 | $-4.88 | $-3.89 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $187500.00 | $187500.00 | $187500.00 | 5 |
| Quarter ending Dec 2026 | $187500.00 | $187500.00 | $187500.00 | 5 |
| Quarter ending Mar 2027 | $500000.00 | $500000.00 | $500000.00 | 4 |
| Quarter ending Jun 2027 | $166667.00 | $166667.00 | $166667.00 | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $234374.00 | $333333.00 | $468749.00 | 6 |
| FY 2027 | $231617.00 | $525000.00 | $926470.00 | 7 |
